WHAT DOES CEPI DO?

CATALYSTS GLOBAL ADVANCEMENT IN VACCINE DEVELOPMENT

The Coalition for Epidemic Preparedness Innovations (CEPI) is a non-profit public-private organisation that promotes and facilitates the innovative development of vaccines against priority diseases, in order to make them available to all. CEPI actively seeks to improve the landscape of global health R&I investments for the development of diagnostics, therapeutics, and vaccines by creating an enabling environment for research, development, manufacturing, and delivery.

FOCUSES ON WHO PRIORITIES

In line with the World Health Organization’s (WHO) priorities, CEPI’s focus is on developing vaccines against unknown pathogens (Disease X), polio, typhoid fever, and malaria. CEPI is also working to strengthen global vaccine development and manufacturing capabilities in Africa.

SUPPORTS CAPACITY-BUILDING EFFORTS

CEPI has doubled its investments in low- and middle-income countries (LMICs), including South Africa and Egypt, to support vaccine development and manufacturing, and to promote equitable access to vaccines.

WHY INVESTING IN CEPI IS THE SMART CHOICE

CEPI is uniquely placed to coordinate, pool and deploy global health R&I investments to achieve this goal.

THERE IS STILL A LOT TO DO

The COVID-19 pandemic has painfully reminded the world of the cost of inaction and of systematic preparedness failures. There is still a lot to do to achieve global immunisation equity and ensure lasting health security for all.

INVESTMENT FOR PREVENTION

$2 BILLION

BUILDING a stronger and more sustainable global response to future pandemics through rapid development and deployment of medical countermeasures.

SPEARHEADS efforts to end preventable diseases, including by driving the development and delivery of affordable, scalable vaccines. CEPI is advancing the development of vaccines against Lassa fever and other priority diseases.

SPEARHEADS efforts to end preventable diseases, including by driving the development and delivery of affordable, scalable vaccines. CEPI is advancing the development of vaccines against Lassa fever and other priority diseases.

CEPI’S FIVE YEAR PLAN (2022-2027)

INVESTMENT FOR PROTECTION

$16 BILLION

REACHES the goal of at least 300 million EUR in CEPI and contributing at least 300 million EUR since its creation 400 million EUR since its creation

PROMOTES greater use of centralised laboratory networks that can coordinate and catalyse the development of international standards for vaccine manufacturing.

PROTECTS VICTIMS OF CURRENT VECTORS

CEPI is partnering with the World Health Organization (WHO) and others to promote global standards for the ethical and equitable development of vaccines.

COLLABORATES WITH THE EU

CEPI co-leads the vaccine pillar (COVAX) of the Access to COVID-19 Tools Accelerator with its country vaccine manufacturer(s) using non-exclusive criteria to fund projects, CEPI requires grantees to promote market entry for safe, effective, and affordable vaccines.

FUNDING IN 2021

$4 BILLION

FUNDING IN 2022

$34 BILLION

FUNDING IN 2023

$16 BILLION

FUNDING IN 2024

$6 BILLION

COVID-19 VACCINES

$9 BILLION

Novavax

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

SARS-CoV-2

$2 BILLION

SARS-CoV-2

$1 BILLION

SARS-CoV-2

$5 BILLION

SARS-CoV-2

$4 BILLION

SARS-CoV-2

$3 BILLION

COVID-19

$2 BILLION

COVID-19

$3 BILLION

COVID-19

$4 BILLION

COVID-19

$5 BILLION

COVID-19

SARS

$1 BILLION

SARS

$2 BILLION

SARS

$3 BILLION

SARS

$4 BILLION

SARS

$5 BILLION

SARS

ZIKA

$1 BILLION

ZIKA

$2 BILLION

ZIKA

$3 BILLION

ZIKA

$4 BILLION

ZIKA

$5 BILLION

ZIKA

Ebola

$1 BILLION

Ebola

$2 BILLION

Ebola

$3 BILLION

Ebola

$4 BILLION

Ebola

$5 BILLION

Ebola

Lassa fever

$1 BILLION

Lassa fever

$2 BILLION

Lassa fever

$3 BILLION

Lassa fever

$4 BILLION

Lassa fever

$5 BILLION

Lassa fever

1. CEPI (2022) CEPI and Institut Pasteur de Dakar partner to advance COVID-19 vaccine manufacturing. Available at: https://cepi.net/news_cepi/covax-manufacturing-task-force/


3. Hatchett, R. (2022) Developing pandemic-busting vaccines in 100 days. CEPI.


6. Avnist, L. (2022) Scientists pinpoint the origins of the coronavirus. Available at: https://www.nature.com/articles/d41586-022-01418-5


10. EUROPEAN COMMISSION (2020) The COVID-19 pandemic has painfully reminded the world of the cost of inaction and of systematic preparedness failures. There is still a lot to do to achieve global immunisation equity and ensure lasting health security for all.


16. WHO (2021) WHO Director General’s opening remarks at the 152nd WHO Executive Board meeting. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-152nd-who-executive-board-meeting